Lilly signs $1.12B deal with Germany-based firm to develop hearing loss treatments
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline of genetic medicines.
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline of genetic medicines.
The Center for AI and Robotic Excellence in Medicine in part seeks to grow knowledge of AI and its uses in medicine and to identify solutions to military and frontier care challenges.
Rural hospitals are among those that are most affected by the financial challenges facing health care institutions in Indiana, according to a new report released by the Indiana Hospital Association.
The Indianapolis-based radiopharmaceutical company built a 150,000-square-foot production facility and plans to add up to jobs.
The new hire succeeds Ernest Vargo II, who retired Jan. 15 after serving as CEO for 15 years.
The fund has secured commitments from Eli Lilly and Co., Corteva Inc., Elanco Animal Health, Indiana University, Parkview Health and the Indiana Economic Development Corp.
Ovarian cancer is the fifth-leading cause of cancer death among women in the United States.
The $435 million campus will include more than 500,000 square feet of advanced laboratory and production space.
During Irwin’s time with Community, the Foundation has raised more than $137 million in donations to be distributed to programs across Community Health Network.
U.S. Food and Drug Administration officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs, including Eli Lilly and Co.’s Zepbound, used to treat obesity.
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Courtney Roberts’ job is to help ensure that when children with serious illnesses, injuries and conditions must be in the hospital, Riley Health is fully funded to meet their medical and care needs and to advance research to also improve care.
Indianapolis-based Eli Lilly and Co. announced Wednesday it intends to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral therapies for inflammatory-mediated diseases.
The Indianapolis-based company received U.S. regulatory approval last week for its second medicine in 18 months in what it describes as the $1.3 billion dog dermatology market.
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
Participants in the program via the Indiana Life Sciences Association can receive significant discounts—up to 75%—off list prices on goods including lab equipment, office supplies, corporate travel and insurance.
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.